Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Study of Lactobacillus Reuteri BGP-014 in Ulcerative Colitis
NCT05118919Phase 2Completed
- Sponsor
- BioGaia AB
- Start
- Feb 2022
- Primary completion
- Dec 2024
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
A Phase 2 trial of lactobacillus reuteri BGP-014 in ulcerative colitis (UC), sponsored by BioGaia AB. Started Feb 2022; status: completed.
02
Drugs
lactobacillus reuteri BGP-014
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT05118919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05118919.